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Abstract 
 
Purpose: Inflammatory cytokines, such as interleukin (IL)-6, are gaining attention as etiologic factors associated 
with discogenic low back pain (LBP). This study evaluated the efficacy and associated adverse events of intradiscal 
injection of interleukin (IL)-6 receptor antibody (tocilizumab) in patients with discogenic LBP. 5 
Methods: Thirty-two consecutive patients received intradiscal injections (2 mL) of 0.5% bupivacaine (control 
group). Thereafter, tocilizumab was intradiscally injected into another 31 consecutive patients, in addition to 1–2 mL 
of 0.5% bupivacaine (tocilizumab group). Prior to the treatment, the pain origin was confirmed in all subjects using 
pain provocation discography and confirming pain relief with 1 mL of 1% xylocaine. To evaluate the effect of 
tocilizumab injection, we compared the two groups before and after treatment using a numerical rating scale (NRS) 10 
and Oswestry disability index (ODI) scores. We also compared tocilizumab-induced pain relief with the grade of 
intervertebral disc (IVD) degeneration. 
Results: At the final observation, 8 weeks after treatment, 30 cases were evaluable in each group. In the tocilizumab 
group, the NRS and ODI scores demonstrated significant improvements at 2 and 4 weeks post-treatment, 
respectively. IVD degeneration did not correlate with improved NRS scores in the tocilizumab group. Local 15 
infection (discitis) was observed in 1 patient in the tocilizumab group. 
Conclusions: Intradiscal injection of tocilizumab demonstrated a short-term analgesic effect in patients with 
discogenic LBP. The present study revealed the clinical relevance of IL-6 to discogenic LBP. Further study is 
required to determine the long-term effects of intradiscal tocilizumab therapy. 
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Introduction 
Low back pain (LBP) is a common complaint among orthopedic patients, with a lifetime prevalence of up to 
84% [1]. LBP is thought to originate from several sources, such as degenerated intervertebral discs (IVDs)
 
[2], facet 
joints [3], and/or other structures [4]. Freemont et al. reported that nerve growth into the intervertebral disc was 
involved in the pathogenesis of chronic LBP [5], and other have reported that IVD abnormalities are related to the 5 
inflammation and axonal growth induced by inflammatory cytokines [6]. The expression of pain-related, 
proinflammatory mediators, such as interleukin (IL)-1, IL-6, and tumor necrosis factor-α, have been identified in 
degenerated IVDs, and may be related to discogenic LBP [6]. To alleviate discogenic LBP, intradiscal injections of 
anesthetic agents and/or steroids have been performed, but the effects remain controversial [7]. 
A previous study reported neither significant pain relief nor ODI score improvement after single intradiscal 10 
injections of the tumor necrosis factor-α inhibitor, etanercept (dose range, 0.1–1.5 mg), into discogenic LBP patients 
[8]. However, the etanercept doses (maximum, 1.5 mg) were lower than the dose used for treatment of rheumatoid 
arthritis (RA; 25 mg/week). Tocilizumab, which is a humanized, anti-IL-6 receptor monoclonal antibody that blocks 
IL-6 from binding to its receptor [9], has shown excellent therapeutic efficacy (prolonged pain relief) in patients 
with RA [10,11], which may be related to its clinically longer half-life. Ohtori et al. also reported that the epidural 15 
administration of tocilizumab into the spinal nerve reduced radicular pain [12], but there are no clinical reports 
describing the use of tocilizumab in patients with degenerative disc disease.  
The current study assessed the pain-relieving effect, effective duration, and adverse events associated with 
intradiscal injection of tocilizumab in patients with discogenic LBP.  
 20 
Materials and Methods 
The ethics committee of our institution approved the protocol used in this study, and the patients provided 
written informed consent prior to participation in this study.  
Beginning in December 2012, we enrolled 88 LBP patients, who were resistant to more than 3 months of 
conservative treatment. The inclusion criteria were: (1) patients with grades III–V IVD degeneration, according to 25 
their Pfirrmann classification following magnetic resonance imaging (MRI) [13],
 
with the degeneration limited to 2 
levels; (2) a numerical rating scale (NRS) score >4 (0, no pain; 10, worst pain); (3) an Oswestry disability index 
(ODI) score >30%, at baseline; and (4) absence of neurological abnormalities, including lower extremity pain or 
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numbness [14]. We excluded patients who had previous histories of lumbar surgery; spine or spinal cord tumors, 
infections, or trauma; and/or other neurologic or psychiatric disorders. Patients were allowed to take nonsteroidal 
anti-inflammatory drugs (NSAIDs) if they had been prescribed before the treatment, without a dosage change 
throughout the study period. 
Discogenic LBP was diagnosed based on pain exacerbation during forward bending. Pain provocation 5 
discography was performed using the non-ionic contrast medium, iohexol (Daiichi-Sankyo, Tokyo, Japan), to 
determine the pain origin [15]. Intradiscal injections were performed as previously reported [16]. In the lateral 
decubitus position, 5 mL of 1% xylocaine (AstraZeneca, Osaka, Japan) was injected along the course of the needle 
from the skin to the IVD. A 22-gauge discography needle was advanced obliquely into the corresponding IVD under 
fluoroscopic guidance. The needle position was confirmed when the tip reached the center of the nucleus pulposus 10 
in the antero-posterior and lateral views. Subsequently, intradiscal injection of iohexol was performed to induce pain. 
After the procedure, we injected 1 mL of 1% xylocaine into the disc to confirm pain relief, in each patient. In 
patients with MRI evidence of 2 degenerated discs, discography was performed simultaneously for both IVDs; the 
IVD inducing the greater pain was selected for treatment. 
 
The final analysis involved 63 patients (34 men, 29 women; average age, 58.2 years). Two or more weeks 15 
post-discography, intradiscal injection of bupivacaine (0.5% bupivacaine, 2 mL; AstraZeneca, Osaka, Japan), alone, 
was performed in 32 consecutive patients (control group). We also injected the offending discs with 40 mg of 
tocilizumab (Chugai Pharmaceutical, Tokyo, Japan) and 1–2 mL of 0.5% bupivacaine in the next 31 consecutive 
patients (tocilizumab group). This study was an open-label, single-institution, unblinded study (Fig. 1). Discography 
and intradiscal injections were performed by 3 physicians with sufficient experience with the procedure. 20 
NRS scores were evaluated at baseline, 1 day, and 1, 2, 4, and 8 weeks after intradiscal injection. The ODI 
scores were also recorded at baseline, and at 4 and 8 weeks post-injection.
 
We compared the time-course changes in 
NRS and ODI scores between the two groups [17]. To evaluate the influence of disc degeneration, we also compared 
the pain relief effect with tocilizumab, based on the grade of disc degeneration.  
Any adverse events were recorded, including local infection, respiratory tract infection, hematoma, nerve injury, 25 
and/or any other possible side effects. 
Data were analyzed using a Mann-Whitney U-test to compare scores between the groups and within the 
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tocilizumab group. For all statistical analyses, P-values < 0.05 were considered statistically significant.  
 
Results  
Thirty patients from each group were evaluable 8 weeks after treatment; 1 patient with discitis was excluded 
from the tocilizumab group, and 2 with insufficient follow-up were excluded from the control group (Fig. 1). The 5 
tocilizumab group included 20 men and 10 women (mean age, 60.6 years), and the control group comprised 12 men 
and 18 women (mean age, 59.7 years). The sex distribution was the only significant difference between the two 
groups (p = 0.038). NSAIDs were used by 26 subjects in the tocilizumab group and 25 in the control group (Table 
1). 
Fig. 2 shows that the NRS pain scores in both groups gradually increased over the 8 weeks following the initial 10 
pain relief. Pain relief was significantly greater in the tocilizumab group than that in the control group at 1 and 2 
weeks, post-intervention (P < 0.05); however, significant differences were not noted at 4 and 8 weeks (Fig. 2). 
Fig. 3 shows significantly lower ODI scores in the tocilizumab group than in the control group at 4 weeks, 
post-intervention (P < 0.05); however, no difference was seen at 8 weeks. 
Differences were never observed between the NRS scores and the degree of disc degeneration in the 15 
tocilizumab group (Fig. 4). 
One patient (non-compromised patient, no history of diabetes, malnutrition, or liver and kidney dysfunction) 
developed an infection after intradiscal tocilizumab injection, and complained of severe LBP on the day after the 
intradiscal injection. Clinical examination and MRI results revealed discitis, which was successfully treated with 
antibiotic administration, except for the residual LBP. No other complications, including local hematomas, systemic 20 
inflammatory reactions, or spinal nerve injuries, were observed. 
 
Discussion  
Previous reports have noted increased expression of proinflammatory cytokines in animals with injured IVDs 
and in humans with degenerated IVDs [18]. Other reports have indicated that overexpression of inflammatory 25 
cytokines, including IL-6, has been strongly linked with discogenic pain [19, 20]. Therefore, we speculated that 
inhibition of IL-6 overexpression might lead to pain relief. However, clinical reports on IL-6 inhibition for 
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discogenic pain have not been previously published. The present study is the first to confirm improved NRS and 
ODI scores after intradiscal injection of tocilizumab, with an effect lasting 2–4 weeks.  
Cohen et al. reported that the intradiscal injection of etanercept (maximum dose, 1.5 mg) was ineffective for 
patients with discogenic LBP [8]. However, their maximum dose injected was approximately 1/20 of that used 
clinically for RA treatment. On the other hand, the current study used 40 mg of tocilizumab, the maximum amount 5 
of intradiscal administration possible, and which is approximately half of the dose used for RA treatment. 
Burke et al. reported that nucleus pulposus from patients suffering from painful degenerative disc disease 
release higher levels of IL-6 [19]. Significant differences were not observed at any time point, between the NRS 
scores and the degree of disc degeneration in the tocilizumab group. This may be due to the interaction of various 
inflammatory cytokines within the cytokine network [21]; the suppression of a single cytokine might provide only a 10 
transient effect. Further research is necessary to clarify the pathomechanism of discogenic pain on the basis of disc 
degeneration and inflammatory cytokines. 
We experienced one case of discitis after tocilizumab administration among the 31 patients (3.0%). The 
incidence of discitis has previously been reported to be 0–4.9% in patients undergoing lumbar discography. 
Therefore, the incidence of discitis observed in this study was consistent with those reported in previous studies [22], 15 
and is likely not related to the intradiscal administration of tocilizumab. 
In this study, we administered intradiscal bupivacaine, commonly used for the diagnosis and treatment of 
discogenic LBP [23], as an analgesic agent. Due to ethical considerations, a single administration of tocilizumab or 
saline was impossible. Although, several authors have reported a toxic effect of bupivacaine on IVD cells, based on 
in vitro studies [24], a radiologic and MRI study by Ohtori et al. failed to find evidence of accelerated disc 20 
degeneration within 5 years, in humans following a single intradiscal injection [25]. 
The present study has some limitations. First, the current study was not a randomized controlled trial; therefore, 
there was a potential for bias. Ideally, a randomized controlled trial and a dose-dependent outcomes trial should be 
conducted in the future. Second, we injected tocilizumab and bupivacaine into IVDs at the same time. To fully 
evaluate the pain-relieving effect of tocilizumab for discogenic pain, a study involving only the injection of 25 
tocilizumab is necessary, although it is ethically difficult. Third, more frequent evaluations of NRS and ODI scores 
may be required to reveal more detailed information on the intradiscal tocilizumab effect. Finally, a longer follow-up 
period is required to examine the pain-relieving effects and impact on IVDs in future studies. 
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In conclusion, intradiscal injection of tocilizumab demonstrated a short-term analgesic effect in patients with 
discogenic LBP, suggesting a clinical correlation between discogenic LBP and IL-6 expression. The clinical 
significance of this new therapy remains to be established. Further investigation into discogenic LBP pathology and 
an evaluation of its long-term pain relieving effect are required. 
 5 
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Figure Legends 
 
Fig. 1 Study flow diagram. The first subjects included 88 patients with low back pain (LBP) who were resistant to 
conservative treatment for >3 months. At the end of the study, 30 cases, in each group, were evaluable 8 weeks after 
intradiscal drug administration. IVD, intervertebral disc; MRI, magnetic resonance imaging  5 
 
Fig. 2 Changes in numerical rating scale scores for low back pain. The scores are significantly lower in the 
tocilizumab group than in the control group at weeks 1 and 2 (P < 0.05) 
 
Fig. 3 Oswestry disability index scores throughout the study period. There is a significant difference between the 10 
groups at 4 weeks (P < 0.05) 
 
Fig. 4 Correlation between the numerical rating scale score and the degree of disc degeneration in the tocilizumab 
group. No differences were observed at any time point 
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Table 1. Patient demographic characteristics. 
 
 Tocilizumab   Control    Statistical 
analysis between 
the groups 
Pfirrmann classification Total Grade 
4 
Grade 
5 
Total Grade 
3 
Grade 
4 
Grade 
5 
 
No. of patients 30 17 13 30 3 17 10  
Sex (male : female) 20 : 10 12 : 5 8 : 5 12 : 18 2 : 1 4 : 13 5 : 5 p = 0.038 
Age (range) (years) 60.6 (30–80) 52.8 
(30–72) 
65.9 
(30–80) 
59.7 
(23–74) 
33.2 
(23–39) 
48.7 
(30–69) 
61.5 
(36–74) 
N.S. 
No. of patients with 2 level 
disc degeneration 
11   8    N.S. 
No. using NSAIDs  26   25    N.S. 
Pain score before injection         
Numerical rating scale 
(NRS) 
8.5 8.4 8.8 8.3 8.1 7.9 8.7 N.S. 
Oswestry disability Index 
(ODI) 
49.1   56.3    N.S. 
Affected disc level         
L1/2 0 0 0 0 0 0 0  
L2/3 1 1 0 0 0 0 0  
L3/4 4 1 3 5 0 3 2  
L4/5 20 11 9 21 2 12 7  
L5/S1 5 4 1 4 1 2 1  
 
N.S.: no significant difference between the groups 
NSAIDs: nonsteroidal anti-inflammatory drugs 5 
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